Harbour BioMed declared that the U.S. FDA has given the go-ahead for the IND application, permitting the initiation of clinical studies for its inaugural Antibody Drug Conjugate (ADC) project, HBM9033.

This article summarized the latest R&D progress of Bromocriptine Mesylate, the Mechanism of Action for Bromocriptine Mesylate, and the drug target R&D trends for Bromocriptine Mesylate.

Monoamine Oxidase(MAO) is a naturally existing oxidase in the human body, located on the outer membrane of mitochondria.

Alkermes Plc is a biopharmaceutical company focused on central nervous system (CNS) disorders such as schizophrenia, depression, addiction, and multiple sclerosis.

The FDA has given Mallinckrodt the green light to market Lisdexamfetamine Dimesylate Capsules, a product intended to mitigate Attention-Deficit/Hyperactivity Disorder (ADHD).

This article summarized the latest R&D progress of Bifonazole, the Mechanism of Action for Bifonazole, and the drug target R&D trends for Bifonazole.

ACE, or angiotensin-converting enzyme, plays a crucial role in the human body by regulating blood pressure and fluid balance.

On September 1, 2023, the NMPA officially approved a new indication for AstraZeneca's blood cancer product, Acalabrutinib, for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On September 1, 2023, Mabspace Biosciences registered an international multicenter Phase III clinical trial on the Drug Clinical Trial Registration and Information Publicity Platform.

Margetuximab is an Fc-optimized monoclonal antibody acting on HER2, which was introduced by Zai Lab from MacroGenics.

On August 31, 2023, Sirnaomics announced positive results from Phase 1 clinical trials of its RNAi therapy STP707 for treating various solid tumors.

Recently, Neurocrine Biosciences announced new data for the VMAT2 inhibitor drug Ingrezza (valbenazine) capsules, including preliminary results from the Phase III KINECT-HD clinical trial.